Regeneron (REGN) Draws Higher Target From TD Cowen

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is included among the 13 Companies that Just Started Paying Dividends.

During the Q4 2025 net call, CEO Leonard Schleifer said Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) delivered dependable gross growth. Fourth-quarter income roseate 3% from a twelvemonth earlier. He said the summation came from double-digit maturation crossed 3 cardinal products.

Global nett income of DUPIXENT climbed 32%. LIBTAYO income accrued 13% connected a constant-currency basis. In the U.S., EYLEA HD stood out, with income up 66%. Schleifer pointed to that show arsenic a wide motion of momentum, peculiarly successful the home market.

He described DUPIXENT arsenic a halfway pillar of the business. The cause is present utilized by much than 1.4 cardinal patients worldwide and remains positioned for further growth. Schleifer besides highlighted advancement astatine LIBTAYO, citing spot successful adjuvant CSCC and rising stock successful precocious non-small compartment lung cancer. In the U.S., helium said the therapy has go the 2nd astir prescribed immunotherapy successful the first-line setting.

Looking ahead, Schleifer laid retired a engaged regulatory and improvement agenda. He said the institution expects astatine slightest 4 FDA approvals, including 3 caller molecular entities crossed antithetic modalities, on with support of the EYLEA HD prefilled syringe.

He besides noted plans to motorboat 18 further Phase III studies implicit the coming years, with full enrollment of astir 35,000 patients. According to Schleifer, the standard of concern is intended to enactment the adjacent question of imaginable blockbuster products.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is simply a afloat integrated biotechnology institution that invents, develops, manufactures, and commercializes medicines for radical with superior diseases.

While we admit the imaginable of REGN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 13 Best February Dividend Stocks To Buy and 14 High Yield Dividend Stocks with Sustainable Payouts

Disclosure: None.